No Data
No Data
Earnings Preview: PHAR to Report Financial Results on October 24
Pharming Group Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Pharming Group(PHAR.US) With Buy Rating, Cuts Target Price to $30
Express News | Pharming Group NV : Oppenheimer Cuts Target Price to $30 From $31
Earnings Call: Pharming Group NV Reports Growth Amid CEO Transition
Earnings Call: Pharming Group NV Sees Robust Growth in Q3, CEO to Step Down
No Data
No Data